Sylvie Bonvalot, MD, PhD, Discusses Selecting Patients With Locally Advanced Sarcoma for Pre and Postoperative Treatment

CancerNetwork® sat down with Sylvie Bonvalot, MD, PhD, at the 2021 ASCO Annual Meeting to talk about treatment options for high-grade or grade II sarcoma.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Sylvie Bonvalot, MD, PhD, from Institut Curie, about standard of care and treatment options for patients with high-grade or grade II sarcoma.

Bonvalot discusses a phase 2/3 trial (NCT02379845) that used the radioenhancer NBTXR3 as a preoperative treatment to radiotherapy for high-grade sarcoma. The findings of this study were positive and reinforced the use of NBTXR3 in patients with locally advanced soft tissue sarcoma.1 In her discussion, she talks about leaning on colleagues across multidisciplinary oncology teams to select patients who are appropriate for treatment.


In locally advanced sarcoma of at least high-grade or grade 2 [disease], the standard treatment is surgery and radiotherapy and more and more of this [is by] local treatment. Radiotherapy is delivered preoperatively because the long-term morbidity is lower than postoperative therapy. There was a trial run by O’Sullivan a few years ago and clearly preoperative radiotherapy had a better outcome in the long term; [however] you cannot do that for everyone.2

When there was indication and sufficient fit for appropriate radiotherapy, we do more of the radiotherapy postoperatively. This is for high-grade locally advanced sarcoma. Concerning chemotherapy, it’s not standard of care. They would debate, it depends on the subtype, but neoadjuvant chemotherapy is still an option in the guidelines; it’s not always the patient. Usually for grade II or III locally advanced sarcoma, standard of care is a radiotherapy and surgery and the option is a chemotherapy for a subgroup of patients with specific subtype, [such as a] young patient because classically it is a little bit difficult for elderly patients. It’s not the standard of care to deliver the chemotherapy for outpatient surgeries and why the standard is radiotherapy and surgery. In this trial we did, we’re discussing [patients] in the multi-disciplinary tumor board. When it was a locally advanced high-grade sarcoma, the conclusion was radiotherapy and surgery, and the trial was proposed to the patient.


1. Bonvalot S, Rutkowski P, Thariat J, et al. Long-term evaluation of the novel radioenhancer NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma treated in the phase II/II Act.In.Sarc trial. . J Clin Oncol. 2021; 39(suppl 15):11544. 10.1200/JCO.2021.39.15_suppl.11544

2. O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235-2241. doi:10.1016/S0140-6736(02)09292-9

Related Videos
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Related Content